Evidence map›Paper›PMID 38931858›Full record

ArticlePharmaceutics2024

Applicability of MDR1 Overexpressing Abcb1KO-MDCKII Cell Lines for Investigating In Vitro Species Differences and Brain Penetration Prediction.

Emőke Sóskuti, Nóra Szilvásy, Csilla Temesszentandrási-Ambrus, Zoltán Urbán, Olivér Csíkvári, Zoltán Szabó, Gábor Kecskeméti, Éva Pusztai, Zsuzsanna Gáborik

Abstract read
In one paragraph

Article in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Emőke SóskutiCharles River Laboratories Hungary, H-1117 Budapest, Hungary.
Nóra SzilvásyCharles River Laboratories Hungary, H-1117 Budapest, Hungary.
Csilla Temesszentandrási-AmbrusCharles River Laboratories Hungary, H-1117 Budapest, Hungary.ORCID 0000-0002-1348-8725
Zoltán UrbánCharles River Laboratories Hungary, H-1117 Budapest, Hungary.
Olivér CsíkváriCharles River Laboratories Hungary, H-1117 Budapest, Hungary.
Zoltán SzabóDepartment of Medical Chemistry, Albert Szent-Györgyi Medical School, University of Szeged, H-6720 Szeged, Hungary.ORCID 0000-0001-8278-8038
Gábor KecskemétiDepartment of Medical Chemistry, Albert Szent-Györgyi Medical School, University of Szeged, H-6720 Szeged, Hungary.ORCID 0000-0002-5584-6869
Éva PusztaiDepartment of Chemical and Environmental Process Engineering, Faculty of Chemical Technology and Biotechnology, Budapest University of Technology and Economics, H-1111 Budapest, Hungary.ORCID 0000-0002-1997-2630
Zsuzsanna GáborikCharles River Laboratories Hungary, H-1117 Budapest, Hungary.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Implementing the 3R initiative to reduce animal experiments in brain penetration prediction for CNS-targeting drugs requires more predictive in vitro and in silico models. However, animal studies are still indispensable to obtaining brain concentration and determining the prediction performance of in vitro models. To reveal species differences and provide reliable data for IVIVE, in vitro models are required. Systems overexpressing MDR1 and BCRP are widely used to predict BBB penetration, highlighting the impact of the in vitro system on predictive performance. In this study, endogenous Abcb1 knock-out MDCKII cells overexpressing MDR1 of human, mouse, rat or cynomolgus monkey origin were used. Good correlations between ERs of 83 drugs determined in each cell line suggest limited species specificities. All cell lines differentiated CNS-penetrating compounds based on ERs with high efficiency and sensitivity. The correlation between in vivo and predicted K

Indexed as

ABCB1 knock-outBBB penetrationBCRPKp,uu,brain predictionMDR1MDR1 inhibitorspreclinical MDR1species differences

Identifiers

PMID38931858
PMCPMC11207571

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.